Source:http://linkedlifedata.com/resource/pubmed/id/16370384
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2005-12-22
|
| pubmed:abstractText |
Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1464-8431
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
604-10
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:16370384-Antibodies, Monoclonal,
pubmed-meshheading:16370384-Clinical Trials as Topic,
pubmed-meshheading:16370384-Drug Evaluation, Preclinical,
pubmed-meshheading:16370384-Drug Industry,
pubmed-meshheading:16370384-Humans,
pubmed-meshheading:16370384-Patents as Topic,
pubmed-meshheading:16370384-RANK Ligand
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Technology evaluation: denosumab, Amgen.
|
| pubmed:affiliation |
Copenhagen University, RASK Osteoporosis Clinic, Department of Medicine, Roskilde County Hospital Koge, Denmark. b.abrahamsen@dadlnet.dk
|
| pubmed:publicationType |
Journal Article
|